What is the share price of 3B Blackbio DX Ltd (3BBLACKBIO) today?
The share price of 3BBLACKBIO as on 18th September 2026 is ₹1296.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on 3B Blackbio DX Ltd (3BBLACKBIO) share?
The past returns of 3B Blackbio DX Ltd (3BBLACKBIO) share are- Past 1 week: -13.08%
- Past 1 month: 9.08%
- Past 3 months: 7.29%
- Past 6 months: 2.60%
- Past 1 year: -8.40%
- Past 3 years: 64.79%
- Past 5 years: 147.29%
What are the peers or stocks similar to 3B Blackbio DX Ltd (3BBLACKBIO)?
The peers or stocks similar to 3B Blackbio DX Ltd (3BBLACKBIO) include:What is the dividend yield % of 3B Blackbio DX Ltd (3BBLACKBIO) share?
The current dividend yield of 3B Blackbio DX Ltd (3BBLACKBIO) is 0.39.What is the market cap of 3B Blackbio DX Ltd (3BBLACKBIO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of 3B Blackbio DX Ltd (3BBLACKBIO) is ₹1109.40 Cr as of 18th September 2026.What is the 52 week high and low of 3B Blackbio DX Ltd (3BBLACKBIO) share?
The 52-week high of 3B Blackbio DX Ltd (3BBLACKBIO) is ₹1750 and the 52-week low is ₹1085.What is the PE and PB ratio of 3B Blackbio DX Ltd (3BBLACKBIO) stock?
The P/E (price-to-earnings) ratio of 3B Blackbio DX Ltd (3BBLACKBIO) is 18.93. The P/B (price-to-book) ratio is 4.09.Which sector does 3B Blackbio DX Ltd (3BBLACKBIO) belong to?
3B Blackbio DX Ltd (3BBLACKBIO) belongs to the Health Care sector & Biotechnology sub-sector.How to buy 3B Blackbio DX Ltd (3BBLACKBIO) shares?
You can directly buy 3B Blackbio DX Ltd (3BBLACKBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
3B Blackbio DX Ltd
3BBLACKBIO Share Price
NSE₹1,296.800.53% (+6.80)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
3BBLACKBIO Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
3BBLACKBIO Performance & Key Metrics
3BBLACKBIO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 19.99 | 4.09 | 0.39% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.79 | 5.87 | 0.48% |
3BBLACKBIO Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
3BBLACKBIO Company Profile
3B Blackbio DX Ltd specializes in PCR-based molecular diagnostic kits, offering a range of products for oncology, infectious diseases, and human genetics, serving diagnostics labs across India.
BIOCON
PE Ratio
160.52
160.52
1Y Return
7.80%
7.80%
Buy Reco %
69.23
69.23
PE Ratio
88.26
88.26
1Y Return
7.46%
7.46%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
94.10
94.10
1Y Return
71.89%
71.89%
Buy Reco %
85.71
85.71
ACUTAAS
PE Ratio
76.18
76.18
1Y Return
125.13%
125.13%
Buy Reco %
88.89
88.89
ONESOURCE
PE Ratio
854.23
854.23
1Y Return
13.87%
13.87%
Buy Reco %
100.00
100.00
3BBLACKBIO Sentiment Analysis
3BBLACKBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
3BBLACKBIO Stock Summary · June 2026
The earnings call underscored a strong financial performance for FY26, with consolidated revenues reaching approximately INR 142 crores and a profit after tax of nearly INR 60 crores, driven by a 10% growth in the molecular diagnostic business. Management expressed confidence in sustaining this growth momentum into FY27, projecting revenue growth of 15% to 20%, potentially reaching INR 175 to 180 crores. However, they acknowledged challenges in domestic revenue growth, which has slowed to 2-3% year-on-year, impacted by high base effects, while anticipating stabilization around 15%. Strategic priorities include international expansion, particularly in Europe, Africa, and Asia Pacific, where TRUPCR Europe has seen a CAGR of about 40%. Management is also focused on regulatory initiatives and M&A opportunities, despite high market valuations complicating negotiations. They aim for a blended EBITDA margin of approximately 45% for FY27, while addressing operational costs and competitive pressures, particularly from smaller players and Chinese firms, to maintain their market share of around 15%.
3BBLACKBIO Stock Growth Drivers
3BBLACKBIO Stock Growth Drivers
8Strong Financial Performance
3B BlackBio Dx Limited reported a robust financial performance for FY26, achieving consolidated revenues of
Growth in Diagnostic Business
The molecular diagnostic business in India grew by about 10%, reaching sales of INR 86.47
3BBLACKBIO Stock Challenges
3BBLACKBIO Stock Challenges
6Declining Domestic Revenue Growth
The company has experienced a significant slowdown in standalone revenue growth, which has dropped to
Increased Depreciation Costs
There has been a notable increase in depreciation costs, which rose to INR 3.9 crores
3BBLACKBIO Forecast
3BBLACKBIO Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
3BBLACKBIO
3BBLACKBIO
Income
Balance Sheet
Cash Flow
Quarterly Normal View
3BBLACKBIO Income Statement
3BBLACKBIO Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 27.19 | 23.13 | 32.58 | 28.41 | 27.44 | 26.55 | 39.41 | 55.93 | 45.58 | 39.63 | ||||||||||
Operating & Other expenses | 13.12 | 8.49 | 12.97 | 10.32 | 14.57 | 10.40 | 19.17 | 28.63 | 26.94 | 24.97 | ||||||||||
EBITDA | 14.07 | 14.64 | 19.61 | 18.09 | 12.87 | 16.15 | 20.24 | 27.30 | 18.64 | 14.66 | ||||||||||
| Depreciation/Amortization | 0.30 | 0.27 | 0.27 | 0.27 | 0.28 | 0.28 | 0.58 | 0.38 | 3.89 | 1.34 | ||||||||||
| PBIT | 13.77 | 14.37 | 19.34 | 17.82 | 12.59 | 15.87 | 19.66 | 26.92 | 14.75 | 13.32 | ||||||||||
| Interest & Other Items | 0.04 | 0.01 | 0.03 | 0.02 | 0.04 | 0.01 | 0.04 | 0.09 | 0.10 | 0.10 | ||||||||||
| PBT | 13.73 | 14.36 | 19.31 | 17.80 | 12.55 | 15.86 | 19.62 | 26.83 | 14.65 | 13.22 | ||||||||||
| Taxes & Other Items | 4.86 | 3.23 | 4.66 | 4.39 | 4.14 | 3.28 | 4.91 | 5.11 | 5.10 | 3.69 | ||||||||||
| Net Income | 8.87 | 11.13 | 14.65 | 13.41 | 8.41 | 12.58 | 14.71 | 21.72 | 9.55 | 9.53 | ||||||||||
| EPS | 10.26 | 13.19 | 17.35 | 15.75 | 9.38 | 14.76 | 17.55 | 26.19 | 11.44 | 10.48 |
3BBLACKBIO Company Updates
3BBLACKBIO Stock Peers
3BBLACKBIO Past Performance & Peer Comparison
3BBLACKBIO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| 3B Blackbio DX Ltd | 18.93 | 4.09 | 0.39% |
| Biocon Limited | 160.52 | 1.69 | 0.13% |
| Anthem Biosciences Limited | 88.26 | 17.17 | 0.22% |
| Sai Life Sciences Limited | 94.10 | 13.22 | — |
3BBLACKBIO Stock Price Comparison
Compare 3BBLACKBIO with any stock or ETFCompare 3BBLACKBIO with any stock or ETF
3BBLACKBIO
3BBLACKBIO Holdings
3BBLACKBIO Shareholdings
3BBLACKBIO Promoter Holdings Trend
3BBLACKBIO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
3BBLACKBIO Institutional Holdings Trend
3BBLACKBIO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
3BBLACKBIO Shareholding Pattern
3BBLACKBIO Shareholding Pattern
3BBLACKBIO Shareholding History
3BBLACKBIO Shareholding History
Foreign Institutions
Mutual Funds Invested in 3BBLACKBIO
Mutual Funds Invested in 3BBLACKBIO
No mutual funds holding trends are available
Top 1 Mutual Funds holding 3B Blackbio DX Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0009% | Percentage of the fund’s portfolio invested in the stock 0.04% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 106/130 (+2) |
Compare 3-month MF holding change on Screener
smallcases containing 3BBLACKBIO stock
smallcases containing 3BBLACKBIO stock
Looks like this stock is not in any smallcase yet.
3BBLACKBIO Events
3BBLACKBIO Events
3BBLACKBIO Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.39%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.87 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
3BBLACKBIO Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.39%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.87 every year
3BBLACKBIO Upcoming Dividends
3BBLACKBIO Upcoming Dividends
Cash Dividend
Ex DateEx DateSep 22, 2026
Final
Final | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Sep 22, 2026
3BBLACKBIO Past Dividends
3BBLACKBIO Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2025
Final
Final | Div/Share: ₹4.00
Dividend/Share
₹4.00
Ex DateEx Date
Sep 19, 2025
Cash Dividend
Ex DateEx DateSep 17, 2024
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 17, 2024
Cash Dividend
Ex DateEx DateSep 15, 2023
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 15, 2023
Cash Dividend
Ex DateEx DateSep 14, 2022
Final
Final | Div/Share: ₹2.50
Dividend/Share
₹2.50
Ex DateEx Date
Sep 14, 2022
Cash Dividend
Ex DateEx DateSep 14, 2021
Special
Special | Div/Share: ₹8.00
Dividend/Share
₹8.00
Ex DateEx Date
Sep 14, 2021
3BBLACKBIO Stock News & Opinions
3BBLACKBIO Stock News & Opinions
Articles & Videos
Earnings
Earnings
3B Blackbio DX Ltd consolidated sales down 5.48% on year in Q2FY2026, net profit slipped by 8.37%3B Blackbio DX Ltd share price gained 3.33% to Rs 1246.65. The Company's net profit eased 8.37% to Rs 8.98 crore, while revenue from operations softened by 5.48% to Rs 33.49 crore in Q2FY26 over Q1FY26. The market capitalization of Healthcare Service Provider industry group stocks on BSE stood at Rs 73454.32 crore, improving 10.78%. It has inched up 3.04% over last one week and jumped by 15.68% in last one month while the market capitalization of 3B Blackbio DX Ltd has marginally improved by 3.54% and 9.16% in the same period respectively. Profit before tax (PBT) of 3B Blackbio DX Ltd stood at Rs 13.22 crore in Q2 FY26, nosediving by 16.65% year-on-year, and declining 9.76% quarter-on-quarter. EBITDA came in at Rs 2 crore, tanking 68.35% YoY and tumbling by 243.37% sequentially. Total expenses dropped by 14.66% to Rs 26.31 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 7.85 crore, inching up 8.13% YoY, while employee benefits expense was at Rs 8.55 crore, dropping 8.65% YoY. For the TTM ended FY26, revenue from operations witnessed a strong growth of 30.15% to Rs 96.47 crore, while net profit soared by 48.57% to Rs 47.69 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 1948% to Rs 35.03 crore, and PBT surged 44.37% to Rs 64.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 43.36 crore in FY26, as against Rs 26.95 crore in FY25. 3B Blackbio DX Ltd nosedived by 19.97% in last one year, underperforming the benchmark BSE Sensex which has slipped by 2.83% during the same period.
1 month agoCapital Market - Live
Corporate
Corporate
3B BlackBio Dx Limited to convene a board meeting on August 13 to review financial resultsKilpest India Limited, now known as 3B BlackBio Dx Limited, will hold a board meeting on Thursday, August 13, 2026, at 3:00 P.M. to approve the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited. The trading window for the company's equity shares will remain closed for designated persons and their immediate relatives from Wednesday, July 1, 2026, and will reopen 48 hours after the results are announced on August 13, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of 3B Blackbio DX recommends final dividend3B Blackbio DX announced that the Board of Directors of the Company at its meeting held on 29 May 2025, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.
3 months agoCapital Market - Live
Corporate
Corporate
3B Blackbio DX to table results3B Blackbio DX will hold a meeting of the Board of Directors of the Company on 29 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
3B Blackbio DX consolidated net profit rises 62.16% in the December 2025 quarterNet profit of 3B Blackbio DX rose 62.16% to Rs 21.73 crore in the quarter ended December 2025 as against Rs 13.40 crore during the previous quarter ended December 2024. Sales rose 98.31% to Rs 50.35 crore in the quarter ended December 2025 as against Rs 25.39 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales50.3525.39 98 OPM %43.1259.39 - PBDT27.2218.06 51 PBT26.8417.80 51 NP21.7313.40 62 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
3B Blackbio DX to conduct board meeting3B Blackbio DX will hold a meeting of the Board of Directors of the Company on 6 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
3B Blackbio DX consolidated net profit rises 0.41% in the September 2025 quarterNet profit of 3B Blackbio DX rose 0.41% to Rs 14.71 crore in the quarter ended September 2025 as against Rs 14.65 crore during the previous quarter ended September 2024. Sales rose 16.30% to Rs 33.90 crore in the quarter ended September 2025 as against Rs 29.15 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales33.9029.15 16 OPM %43.4555.47 - PBDT20.2019.58 3 PBT19.6219.31 2 NP14.7114.65 0 Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
3B Blackbio DX to table results3B Blackbio DX will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
3B Blackbio DX schedules AGM3B Blackbio DX announced that the Annual General Meeting(AGM) of the company will be held on 26 September 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Corporate
Corporate
3D Blackbio DX to convene board meeting3D Blackbio DX will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live
1 year agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -6.12%, vs industry avg of 18.09%
Over the last 5 years, market share decreased from 1.93% to 0.6%
Over the last 5 years, net income has grown at a yearly rate of -12.44%, vs industry avg of 11.18%